Xenon Pharmaceuticals

About:

Xenon Pharmaceuticals operates as a neurology-focused biopharmaceutical company.

Website: http://www.xenon-pharma.com

Twitter/X: XenonPharma

Top Investors: Takeda, New Enterprise Associates, Neurocrine Biosciences, InterWest Partners, Novo Ventures

Description:

Xenon Pharmaceuticals is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits or phenotypes. They apply their expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, they gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, they are developing proprietary product candidates to treat both orphans as well as more prevalent diseases

Total Funding Amount:

$1.29B

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Burnaby, British Columbia, Canada

Founded Date:

1996-01-01

Contact Email:

investors(AT)xenon-pharma.com

Founders:

Simon Pimstone

Number of Employees:

101-250

Last Funding Date:

2023-11-29

IPO Status:

Public

© 2025 bioDAO.ai